Radioligand Therapy and Molecular Imaging for Prostate and Neuroendocrine Cancers
This community focuses on the development and clinical application of targeted radionuclide therapies and advanced molecular imaging techniques, primarily for the diagnosis and treatment of metastatic prostate cancer and neuroendocrine tumors.
The research centers on the use of specific radiotracers, such as PSMA-targeting agents for prostate cancer and somatostatin analogs for neuroendocrine tumors, to deliver targeted radiation directly to malignant cells. Key methodologies include Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT) for precise tumor localization and response evaluation. The work frequently involves the clinical management of castration-resistant prostate cancer and the assessment of metastatic disease in bone and lymph nodes. Recurring themes include the integration of diagnostic imaging with therapeutic interventions, often referred to as theranostics, and the evaluation of treatment efficacy in patients with advanced-stage carcinomas.
The largest share of this research is found in Technetium studies, accounting for 41.4% of all Technetium research, and Lutetium studies, representing 30.8% of all Lutetium research. Technetium also contributes the highest raw paper count within this group, with 4,663 papers.
The community comprises 59,047 papers, published predominantly in the European Journal of Nuclear Medicine and Molecular Imaging, Clinical Nuclear Medicine, and the Journal of Nuclear Medicine.
Recent work continues to focus on the clinical application of PSMA-targeted therapies for metastatic prostate cancer and the diagnostic refinement of neuroendocrine tumor management, with recent trials evaluating the combination of radioligand therapy with standard hormonal treatments.